NIS793
- Generic Name
- NIS793
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
- Conditions
- Resectable Pancreatic CancerPancreatic CancerBorderline Resectable Pancreatic AdenocarcinomaPancreatic Adenocarcinoma
- Interventions
- Drug: mFOLFIRINOXRadiation: ChemoradiationProcedure: Surgery
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Kimberly Perez, MD
- Target Recruit Count
- 8
- Registration Number
- NCT05546411
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
FOLFIRINOX + NIS793 in Pancreatic Cancer
- Conditions
- Pancreas CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
- Interventions
- Radiation: ChemoradiationRadiation: Radiation TherapyProcedure: Surgery
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Colin D. Weekes, M.D., PhD
- Target Recruit Count
- 4
- Registration Number
- NCT05417386
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT04952753
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of Michigan Medical, Ann Arbor, Michigan, United States
🇺🇸WA Uni School Of Med, Saint Louis, Missouri, United States
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 511
- Registration Number
- NCT04935359
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸University of California LA, Los Angeles, California, United States
🇺🇸Advent Health Cancer Institute, Orlando, Florida, United States
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT04810611
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center ., Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital ., Boston, Massachusetts, United States
🇺🇸City Of Hope National Med Center Oncology, Duarte, California, United States
Study of Select Combinations in Adults With Myelofibrosis
- Conditions
- Primary MyelofibrosisMyelofibrosisPMFPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis
- Interventions
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04283526
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04097821
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
- Conditions
- Breast CancerColorectal CancerLung CancerRenal CancerHepatocellular CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT02947165
- Locations
- 🇺🇸
Sarah Cannon Research Institute SC, Nashville, Tennessee, United States
🇺🇸Huntsman Cancer Institute SC, Salt Lake City, Utah, United States
🇨🇳Novartis Investigative Site, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.